The primary endpoints of this study were (i) the association between ADGRG6 expression and patient prognosis and (ii) the functional and mechanistic evidence linking ADGRG6 to tumor progression and immune regulation in PAAD. The gene discussed is ADGRG6; the disease is pancreatic adenocarcinoma.